Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Total Debt

Short-term and long-term borrowings combined.

Upstream Bio, Inc.NASDAQ: UPB

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 34.5% from a year ago

Total debt stood at $1.11M at the end of Q1 FY2026, down 34.5% from a year earlier and down 12.2% from the prior quarter. Over 3 fiscal years it compounded at +138.1% a year.

Context

  • Total debt amounted to 0.4% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -34.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.11M-12.2% QoQ
Last fiscal yearDec 2025
$1.27M-30.8% YoY
Year agoMar 2025
$1.7M-34.5% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.5%——
1 year-30.8%——
3-year CAGR+138.1%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
1.27M USD
Year-over-year change
-30.8%
3-year CAGR
+138.1%

Total Debt vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -34.5% is the lowest of 9, against a peer median of -3.0%.
  • Total debt amounts to 0.4% of total assets for UPB, versus a peer median of 3.2%.
UPB Competitors
Total Debt for UPB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZBIOZenas BioPharma, Inc.Mar 2026$351.73M USD+28612.6%+274.1%47.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$345.36M USD+18700.2%+568.3%73.1%
NVAXNovavax, Inc.Mar 2026$295.06M USD+29.0%-23.2%28.3%
NTLAIntellia Therapeutics, Inc.Mar 2026$80.49M USD-32.5%-10.6%10.6%
RLAYRelay Therapeutics, Inc.Jun 2026$30.66M USD-10.3%-17.5%3.2%
WVEWave Life Sciences Ltd.Mar 2026$15.72M USD-33.4%-22.1%2.7%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$4.94M USD-16.7%-1.7%0.6%
UPBUpstream Bio, Inc.Mar 2026$1.11M USD-34.5%+138.1%0.4%
PHVSPharvaris N.V.Sep 2026€603.94K EUR+4.4%+21.2%0.2%
SYRESpyre Therapeutics, Inc.Sep 2026$0 USD——0.0%
Peer median (excluding UPB) —-3.0%-6.2%3.2%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.05M25.83M325.89M101.58M
Short-term Investments083.98M144.56M239.93M
Net Receivables412K236K1.18M668K
Inventory0000
Other Current Assets233K370K494K9.62M
Total Current Assets18.31M117M479.16M351.8M
Property, Plant & Equipment (Net)164K202K2.37M1.78M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets7K(1)194K194K
Total Non-current Assets171K202K2.56M1.98M
Total Assets18.48M117.2M481.72M353.77M
Account Payables712K1.99M4.04M2.73M
Short-term Debt000720K
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities893K2.17M2.7M10.01M
Total Current Liabilities4.86M6.52M10.74M13.45M
Long-term Debt000549K
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities119.77M233.81M00
Total Non-current Liabilities119.78M233.81M1.13M549K
Total Liabilities124.63M240.32M11.87M14M
Common Stock3K3K53K54K
Retained Earnings(107.44M)(127.97M)(190.78M)(334.22M)
Accumulated OCI021K(25K)530K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(106.16M)(123.13M)469.85M339.77M
Total Debt94K45K1.83M1.27M
Net Debt(16.96M)(25.79M)(324.06M)(100.31M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.